Suppliers / Qilu Antibiotics Pharmaceutical

Qilu Antibiotics Pharmaceutical

China Updated 9 July 2026

Qilu Antibiotics Pharmaceutical is an API and finished-dose manufacturer based in China. It holds 5 active US drug master files across a filed portfolio of 10 molecules. Its filings concentrate with JFDA (JO), MINSA (CR) and EDE (AE). Its GMP standing is certified by ANVISA (Brazil) and US FDA. Its most recent recorded inspection, by US FDA, closed on 30 May 2023 as VAI.

5
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
12
filings across 5 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 30 May 2023 VAI US FDA
  • 16 August 2018 NAI US FDA
  • 22 September 2015 VAI US FDA
  • 20 September 2013 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Jinan, United Arab Emirates Not on file
JINAN, China Not on file
China, China 3009831352

What they file, and where

Molecule Regulators Docs
Cefixime SFDA (Saudi Arabia), US FDA 3
Ceftazidime SFDA (Saudi Arabia), US FDA 3
Cefepime Dihydrochloride SFDA (Saudi Arabia) 2
Avibactam SFDA (Saudi Arabia) 1
Cefazolin SFDA (Saudi Arabia) 1
Cefepime US FDA 1
Cefpodoxime US FDA 1
Cefprozil US FDA 1
Ceftriaxone SFDA (Saudi Arabia) 1
Cefuroxime SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
JFDA (JO) 4 None
MINSA (CR) 3 None
EDE (AE) 3 None
ARCSA (EC) 1 None
DIGEMAPS (DO) 1 None
ANVISA (Brazil) None 1
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Qilu Antibiotics Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 5 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 30 May 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates